Pharmaceuticals News and Research

RSS

Resurgence in cardiovascular R&D is urgently needed to curb new epidemic of CVD

A resurgence in cardiovascular R&D is urgently needed to curb a new epidemic of cardiovascular diseases, according to leading cardiologists and industry representatives in the Cardiovascular Round Table (CRT).

10 Jul 2013

Immunocore, GSK partner for cancer targeting ImmTACs

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs called ImmTACs to treat cancer and viral disease, today announced it has entered into a partnership with GlaxoSmithKline (GSK) for multiple novel targets not addressable using antibody-based technologies. This is Immunocore’s second major partnership this year.

10 Jul 2013

Study reveals that contaminated ultrasound gel causes healthcare-associated infection

After a 2011 outbreak of P. aeruginosa, investigators at Beaumont Health System near Detroit, Michigan determined contaminated ultrasound gel was the source of bacteria causing the healthcare-associated infection.

10 Jul 2013

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the Therapeutic Goods Administration of Australia has approved KALYDECO (ivacaftor) for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.

10 Jul 2013

Boehringer Ingelheim signs multi-year renewal agreement to NextBio Research Platform

NextBio, whose Big Data technology enables users to apply genomic data from disparate sources in novel and useful ways across life sciences research, today announced that Boehringer Ingelheim has signed a multi-year renewal agreement to the NextBio Research Platform.

9 Jul 2013

Viewpoints: Health care's hidden consensus; Examining the fee-for-service payment system; Alternative medicine's allure

The politicians' consensus is that health care reform shouldn't alter or disrupt the way the majority of Americans get their insurance today. ... The policy consensus, though, is that the status quo is actually the problem, and that it deserves to be threatened, undermined and replaced as expeditiously as possible. Wonks of the left and right disagree on what that replacement should look like. But they're united in regarding employer-provided coverage as an unsustainable relic (Ross Douthat, 7/6).

9 Jul 2013

Glythera secures £700k to advance development of new generation of biological therapeutics

Glythera Ltd is delighted to announce that it has successfully achieved a number of technical and commercial milestones which has resulted in the release of a second tranche of funding totalling £700k from IP Group and its managed fund, the Finance for Business North East Technology Fund.

9 Jul 2013

Omthera submits Epanova NDA to FDA for treatment of severe hypertriglyceridemia

Omthera Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of Epanova™ for the treatment for patients with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500mg/dL).

9 Jul 2013

Atomo Diagnostics, BBI Solutions sign agreement for global rollout out of AtomoRapid test

Medical technology developer Atomo Diagnostics and market leading diagnostic company BBI Solutions have entered into an agreement to commercialise Atomo’s award winning, integrated rapid blood test platform, AtomoRapid.

9 Jul 2013

Cancer immunotherapies promise to be a new tool in fight against cancer

Drugs that direct a cancer patient's immune system to eradicate her or his disease, known as cancer immunotherapies, promise to be a new tool in the fight against cancer. Since the Koch Institute's inception, exploring the close relationship between the immune system and cancer has been one of the Institute's priority research areas.

9 Jul 2013

PHT announces availability of LogPad App System for clinical trial patients

PHT Corporation announced the general availability of the LogPad App™ System that collects compliant patient data using Apple and Android smartphones. The LogPad App gives sponsors and CROs the flexibility to deploy Phase II, III, and IV clinical studies plus post market and observational research to massive patient populations.

9 Jul 2013

Soligenix announces personalized medicine collaboration with SciClone

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced a personalized medicine collaboration with SciClone Pharmaceuticals in the Company's oral mucositis clinical program with SGX942.

8 Jul 2013

Bayer starts enrollment in BAY94-9027 Phase II/III trial for hemophilia A in children

Bayer HealthCare today announced the company has started to enroll patients in an international Phase II/III trial to evaluate its investigational compound BAY94-9027 for the treatment of hemophilia A in children.

8 Jul 2013

Researchers develop new PET tracer to better monitor the progress of cancer and cancer therapy

Imaging techniques in cancer medicine provide far more than merely information on the scale and location of cancerous ulcers. There are modern methods that additionally characterise the tumour cells precisely, for instance by specific molecules they carry on their surface. Such additional information gives doctors key clues as to the precise cancer type and enables them to predict the probability that a patient will respond to a particular form of therapy.

6 Jul 2013

Oncologist urges drug companies to include key information in cancer drug labels

In the July 10th issue of The New England Journal of Medicine, Dr. Basch calls for pharmaceutical manufacturers to collect rigorous information on how drugs impact symptoms and quality of life starting early in drug development, and for the U.S. Food and Drug Administration (FDA) to include this information in drug labels.

5 Jul 2013

Pharmaceuticals News and Research

Resurgence in cardiovascular R&D is urgently needed to curb new epidemic of CVD

Immunocore, GSK partner for cancer targeting ImmTACs

Study reveals that contaminated ultrasound gel causes healthcare-associated infection

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Boehringer Ingelheim signs multi-year renewal agreement to NextBio Research Platform

Viewpoints: Health care's hidden consensus; Examining the fee-for-service payment system; Alternative medicine's allure

Glythera secures £700k to advance development of new generation of biological therapeutics

Omthera submits Epanova NDA to FDA for treatment of severe hypertriglyceridemia

Atomo Diagnostics, BBI Solutions sign agreement for global rollout out of AtomoRapid test

Cancer immunotherapies promise to be a new tool in fight against cancer

PHT announces availability of LogPad App System for clinical trial patients

Soligenix announces personalized medicine collaboration with SciClone

Bayer starts enrollment in BAY94-9027 Phase II/III trial for hemophilia A in children

Researchers develop new PET tracer to better monitor the progress of cancer and cancer therapy

Oncologist urges drug companies to include key information in cancer drug labels

CEA-Leti receives €1M from bpifrance to accelerate the development of liver-cancer detection system

Roche introduces new metabolite tests for cell fermentation analytics

ERYTECH reports fast take-off of GRASPA Phase IIb trial in patients with acute myeloid leukemia

FDA approves Orexo's Zubsolv for people suffering from opioid dependence

Data on side effects of fidaxomicin not analysed appropriately

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence